Other substances

Lifirafenib

A B-raf kinase and epidermal growth factor receptor inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Lifirafenib (BGB-283) is an experimental drug that selectively binds to and inhibits the activity of protein kinase B-raf and epidermal growth factor receptor. It has been trialled for potential inhibitory effect on certain solid tumours (NCIt, NCT03641586).

Lifirafenib on DrugBank
Lifirafenib on PubChem

Synonyms

Beigene-283; BGB-283

 

Structure image - Lifirafenib

C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Export (.csv)